Unité de Fabrication des Médicaments S.A

BVMT:UMED Stock Report

Market Cap: د.ت232.6m

Unité de Fabrication des Médicaments Past Earnings Performance

Past criteria checks 4/6

Unité de Fabrication des Médicaments's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 1.6% per year. Unité de Fabrication des Médicaments's return on equity is 13.8%, and it has net margins of 11.4%.

Key information

-20.3%

Earnings growth rate

-20.3%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate1.6%
Return on equity13.8%
Net Margin11.4%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Unité de Fabrication des Médicaments makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BVMT:UMED Revenue, expenses and earnings (TND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2311513180
31 Mar 2310610170
31 Dec 22968170
30 Sep 22916170
30 Jun 22865170
31 Mar 22857160
31 Dec 21859150
30 Sep 21857150
30 Jun 21866150
31 Mar 21897150
31 Dec 20917150
30 Sep 209310150
30 Jun 209512150
31 Mar 2010115150
31 Dec 1910718150
30 Sep 1910720150
30 Jun 1910722140
31 Mar 199720140
31 Dec 188718130
30 Sep 188016130
30 Jun 187313130
31 Mar 187213130
31 Dec 177013120
30 Sep 176912120
30 Jun 176811110
31 Mar 176611110
31 Dec 166511100
30 Sep 166313100
30 Jun 16611590
31 Mar 16601490
31 Dec 15591390
30 Sep 15601290
30 Jun 15601180
31 Mar 15591280
31 Dec 14581280
31 Dec 13471080

Quality Earnings: UMED has high quality earnings.

Growing Profit Margin: UMED's current net profit margins (11.4%) are higher than last year (5.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: UMED's earnings have declined by 20.3% per year over the past 5 years.

Accelerating Growth: UMED's earnings growth over the past year (158.3%) exceeds its 5-year average (-20.3% per year).

Earnings vs Industry: UMED earnings growth over the past year (158.3%) exceeded the Pharmaceuticals industry -4.8%.


Return on Equity

High ROE: UMED's Return on Equity (13.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.